Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

CMB-401, an immunoconjugate for the targeted treatment of EOC

June 25, 1998

Positive phase II results for GMK vaccine presented at NCI-EORTC meeting

June 25, 1998

NeoRx begins phase I trial of Pretarget technology in lymphoma

June 25, 1998

Progenics receives payment for cancer vaccine milestone

June 24, 1998

IL-2 fusion protein produces remission in late-stage refractory CTCL

June 23, 1998

Novopharm Biotech's NOVOMAb-G2 IgM completes phase I

June 23, 1998

Russian scientists evaluate the antitumor activity of betaleukin

June 22, 1998

CBER requests additional information for Ontak BLA

June 19, 1998

ICO25 MAb suppresses tumor growth and prolongs survival in preclinical model of colon cancer

June 19, 1998

New dosing regimen of Avax melanoma vaccine results in improved outcome

June 17, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.